We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

37 hedge funds and large institutions have $104M invested in Quince Therapeutics in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.05% more ownership

Funds ownership: 0% → 0.05% (+0.05%)

Holders
37
Holders Change
+37
Holders Change %
–
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
37
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SUT
SC US (TTGP)
California
+$31.1M
2
AI
Alphabet Inc
California
+$13.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$5.22M
4
BlackRock
BlackRock
New York
+$4.16M
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
+$2.99M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SUT
1
SC US (TTGP)
California
$44.2M +$31.1M +5,202 New
AI
2
Alphabet Inc
California
$19.3M +$13.6M +2,269 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.43M +$5.22M +874 New
BlackRock
4
BlackRock
New York
$5.93M +$4.16M +697 New
Manulife (Manufacturers Life Insurance)
5
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4.25M +$2.99M +500 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$3.08M +$2.17M +363 New
DCM
7
DAFNA Capital Management
California
$2.78M +$1.95M +327 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.29M +$1.61M +270 New
OAM
9
Oxford Asset Management
United Kingdom
$2.25M +$1.58M +265 New
Goldman Sachs
10
Goldman Sachs
New York
$2.05M +$1.44M +241 New
Morgan Stanley
11
Morgan Stanley
New York
$1.97M +$1.39M +232 New
Charles Schwab
12
Charles Schwab
California
$1.05M +$741K +124 New
Northern Trust
13
Northern Trust
Illinois
$991K +$699K +117 New
State Street
14
State Street
Massachusetts
$976K +$1.15M +192 New
DIM
15
DC Investments Management
Virginia
$776K +$544K +91 New
N
16
Nuveen
North Carolina
$654K +$460K +77 New
LCM
17
Landscape Capital Management
New Jersey
$535K +$376K +63 New
Millennium Management
18
Millennium Management
New York
$531K +$370K +62 New
SSA
19
Schonfeld Strategic Advisors
New York
$489K +$347K +58 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$349K +$245K +41 New
UBS Group
21
UBS Group
Switzerland
$290K +$203K +34 New
CS
22
Credit Suisse
Switzerland
$289K +$203K +34 New
Barclays
23
Barclays
United Kingdom
$253K +$179K +30 New
Bank of America
24
Bank of America
North Carolina
$239K +$167K +28 New
Wells Fargo
25
Wells Fargo
California
$191K +$131K +22 New
1
2

QNCX Hedge Fund Activity: Q2 2019 in Review

37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2019, worth a combined $104M.

Buyers outnumbered sellers: 37 funds opened new QNCX positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SC US (TTGP), opening a new position worth an estimated $31.1M.

  • 37 institutional investors held Quince Therapeutics (QNCX) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $104M of Quince Therapeutics stock for Q2 2019.
  • 37 funds opened new Quince Therapeutics positions in Q2 2019 and 0 closed out, a net change of +37 holders.
  • The largest Quince Therapeutics buyer in Q2 2019 was SC US (TTGP), an estimated $31.1M added.

Based on aggregated 13F filings for Q2 2019.